24 In RAS & BRAF WT mCRC, Intensive Therapy with FOLFOXIRI + Either EGFR Inhibitors or Bevacizumab Results in High ORR TRIP Study 1 BRAF WT (n = 37) TRIP + MACBETH Study 2 BRAF WT (n = 37 + 64) TRIBE 2 BRAF WT (n = 62) FOLFOXIRI + Panitumumab FOLFOXIRI + Anti-EGFR FOLFOXIRI + Bevacizumab CR04%3% PR86.5%78%71% SD10.8%13%27% PD2.7%5%2% Overall response rate*86%82%71% *P =.120, Fisher's exact test.
{}